Galapagos' Latest Advance: Its Licensing Deal with Janssen

By Business Review Editor

Pharma Deals Review: Vol 2007 Issue 90 (Table of Contents)

Published: 1 Dec-2007

DOI: 10.3833/pdr.v2007.i90.245     ISSN: 1756-7874

Section: Features

Fulltext:

Abstract

On the back of the successful building of its service division, BioFocus DPI, Galapagos has licensed its rheumatoid arthritis programme to Janssen Pharmaceutica (of Johnson and Johnson) in highly lucrative deal that could earn the company in excess of US$1 B...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details